Načítá se...
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era of anti-tumor therapy, with sustained responses and significant survival advantages observed in multiple tumors, most patients do not benefit. Therefore, more and more attention has been paid to...
Uloženo v:
| Vydáno v: | Biomark Res |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7450548/ https://ncbi.nlm.nih.gov/pubmed/32864131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00209-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|